Creso Pharma Ltd (ASX:CPH, OTCQB:COPHF) has secured A$500,000 in funding from Obsidian Global GP, LLC, trading some 340,000 convertible notes under the second purchase of a convertible note facility with Obsidian announced late last year.
Under the drawdown, Creso will issue almost 13 million collateral shares and 22 million listed options trading on the ASX under the code CPHO – the options will have a strike price of A$0.25.
This drawdown adds to funding recently secured from share placements, wherein shareholders approved A$2 million of director participation in prior placements.
Valuable strategic relationship
“We are pleased to have further progressed our relationship with Obsidian,” Creso Pharma CEO and managing director William Lay said.
“Obsidian has a successful track record of supporting ASX-listed growth companies and we believe there is significant value to having a flexible capital partner.
“Additionally, shareholder approval of director participation in prior placements provides significant additional capital.
“Creso remains well positioned to deliver shareholder value via ongoing penetration into the various, high growth, plant-based verticals that it currently resides in, and we look forward to providing additional updates to our shareholders as these opportunities crystallise.”
Creso Pharma is developing pharmaceutical cannabis-based products for people and animals, targeting therapeutic, nutraceutical and lifestyle products with wide patient and consumer reach for human and animal health.